A flexible stem, soft tip, and resilient reservoir enable rapid oral animal vaccination with lower anxiety, safer handling, and low residual volume.
H2O2 treatment simultaneously fragments and purifies bacterial polysaccharides, cutting impurities while preserving vaccine-relevant structure.
A multivalent canine vaccine using non-Grippotyphosa serovars broadens protection to Grippotyphosa and reduces leptospirosis symptoms.
A multivalent canine vaccine using non-Icterohaemorrhagiae serovars induces cross-protection and reduces leptospirosis symptoms.
Matrix-bound vesicles boost vaccine immune response and antibody production while avoiding the toxicity, granulomas, and abscesses linked to traditional adjuvants.
Targeting the C. acnes CAMP virulence factor, this recombinant vaccine induces specific immunity to curb inflammation without broad antibiotic drawbacks.
A scaffold-plus-repeat fusion antigen boosts C. difficile toxin neutralization 10-100 fold while remaining suitable for large-scale manufacture.
A lyophilized Pediococcus acidilactici strain suppresses gut pathogens and oxidative stress while remaining active across pH and temperature changes.
Deleted antigen genes let a modified BCG vaccine preserve TB protection while avoiding interference with standard skin tests.
Engineered live bacteria are given a built-in short lifespan to deliver therapeutic effect, then die to limit pathogenesis risk.
Local bladder delivery of a FimH nanoparticle vaccine with Th1-skewing adjuvants boosts bacterial clearance and helps prevent recurrent UTIs.
A lyophilized single-vial vaccine uses metabolizable oil and cake-forming excipients to stay stable without cold-chain storage.
Microbiota-derived peptide analogs prime cross-reactive T cells against tumor antigens while helping limit immune tolerance and autoimmunity.
An adjuvant-free streptococcal vaccine uses inactivated bacteria and PsaA expression to broaden serotype coverage while reducing side effects.
Unnatural amino acid insertion and click-linked liposomes enable uniform fHBP lipidation, broader MenB coverage, and fewer side effects.
Combining fHbp v1, v2, and v3 in one antigen with lower OMV content broadens meningococcal coverage and reduces fever on co-administration.
A fused toxin A and toxin B receptor-binding polypeptide improves CDAD vaccine protection while avoiding full-toxin stability and yield issues.
A fusion protein antigen with ISA201VG emulsion extends Mhp subunit vaccine protection in pigs while simplifying safer administration.
In ovo delivery of lyophilised adult chicken intestinal extract helps establish gut microbiota before hatching, improving immunity and pathogen resistance.